Skip to main content
letter
. 2009 Aug 17;53(11):4955–4956. doi: 10.1128/AAC.00547-09

TABLE 1.

Antimicrobial data for E. coli N08-1503 and the transformants harboring pT168a

E. coli strain Disk diameter (mm)
MIC (μg/ml)
Broth microdilution
ESBL Etest
Etest
Cefotaximeb Cefotaxime-CLAc Ceftazidimeb Ceftazidime-CLAc Cefpodoximeb Cefpodoxime-CLA Cefotaximeb Cefotaxime-CLA Ceftazidimeb Ceftazidime-CLAc Cefpodoximeb Cefpodoxime-CLA Cefepime Cefepime-CLA Cefotaxime Cefotaxime-CLAd Ceftazidime Ceftazidime-CLAd Cefepime Cefepime-CLAe Amoxicillin-CLA Pipercillin-TZBg Cefoxitin
N08-1503 (pT168) 23 (pos) 24 (neg) 8 (pos) 11 (neg) 20 (neg) 15 ≤0.25 (neg) ≤0.12 4 (pos) 2 (neg) 8 (pos) 0.5 8 ≤0.125 0.25 0.094 (neg) 3 0.75 (neg) 2 0.094 (pos) 32 >256 12
DH10B (pT168) 26 (pos) 30 (neg) 8 (pos) 10 (neg) 20 (neg) 16 ≤0.25 (neg) ≤0.12 4 (pos) 1 (neg) 4 (neg) 0.25 4 ≤0.125 0.25 0.094 (neg) 3 1 (neg) 2 0.094 (pos) 64 >256 6
DH10B 29 (neg) 33 16 (pos) 18 (neg) 27 (neg) 21 ≤0.25 (neg) ≤0.12 ≤0.25 (neg) 0.25 1 (neg) ≤0.125 ≤0.25 ≤0.125 <0.25 0.094 (neg) 1 0.38 (neg) <0.25 <0.25 (neg) 3 1.5 8
a

CLA, clavulanic acid; TZB, tazobactam; pos, positive; neg, negative.

b

Data in parentheses are the interpretations for the screen for ESBL according to CLSI document M100-S19 (2).

c

Data in parentheses are the interpretation for confirmation of ESBL according to CLSI document M100-S19 (2).

d

Data in parentheses are the interpretation for confirmation of ESBL according to the manufacturer's instructions in document 75001448-MH0383 (Etest for detection of ESBL; AB bioMérieux, Solna, Sweden). The overall interpretation of the phenotype is non-ESBL producer as both strips were negative.

e

Data in parentheses are the interpretation for confirmation of ESBL according to the manufacturer's instructions in document 75002213-MH0344 (Etest for detection of ESBL; AB bioMérieux, Solna, Sweden). The overall interpretation of the phenotype is ESBL producer as one strip was positive.